BACKGROUND/AIMS: Previous reports state that there is absorption of bismuth
through active peptic ulcers. It was therefore of interest to investigate
the extent of absorption in patients at the ulcer and post-ulcer stages.
METHODOLOGY: Twenty H. pylori-positive patients with gastroscopically verif
ied gastric or duodenal ulcers were randomly allocated to ingest 3000mg bis
muth subnitrate (BSN) (10 patients) or 480mg colloidal bismuth subcitrate (
CBS) (10 patients). Bismuth serum concentration in 12 samples drawn during
the first 4 hours after drug intake was analyzed and the area under the cur
ve (Bi-AUC) was calculated. Anti-H. pylori therapy with amoxicillin and lan
zoprazole eradicated H. pylori in 10 patients and healed the ulcers in all
patients 4 weeks after therapy ended, then the bismuth absorption test was
repeated.
RESULTS: There was no significant difference between ulcer- and post-ulcer
Bi-AUC for patients receiving BSN or for patients receiving CBS. On a molar
basis, CBS gave a 17.4-fold greater absorption of bismuth compared to BSN.
CONCLUSIONS: The presence of an active ulcer does not significantly influen
ce the absorption of bismuth from CBS or BSN.